Market Closed -
Nasdaq
04:00:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
0.7211
USD
|
-2.53%
|
|
+4.46%
|
-38.89%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
292.4
|
214.2
|
21.61
|
25.23
|
21.85
|
-
|
-
|
Enterprise Value (EV)
1 |
292.4
|
214.2
|
-30.85
|
25.23
|
21.85
|
21.85
|
21.85
|
P/E ratio
|
-
|
-
|
-0.33
x
|
-0.62
x
|
-0.68
x
|
-0.94
x
|
-0.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
25.1
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
25.1
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-128
x
|
-6.36
x
|
-0.36
x
|
-
|
-0.81
x
|
-0.53
x
|
-0.38
x
|
FCF Yield
|
-0.78%
|
-15.7%
|
-276%
|
-
|
-124%
|
-188%
|
-265%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
13,984
|
21,021
|
21,190
|
21,381
|
29,534
|
-
|
-
|
Reference price
2 |
20.91
|
10.19
|
1.020
|
1.180
|
0.7211
|
0.7211
|
0.7211
|
Announcement Date
|
3/22/21
|
3/29/22
|
3/28/23
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.87
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.0448
|
-10.71
|
-62.66
|
-71.1
|
-42.61
|
-28.73
|
-35.4
|
-56
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-6,436.78%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-65.37
|
-40.16
|
-28.92
|
-34.8
|
-54
|
Net income
1 |
-
|
-
|
-
|
-65.37
|
-40.16
|
-33.88
|
-33.77
|
-54
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-6,206.9%
|
EPS
2 |
-0.0100
|
-
|
-
|
-3.110
|
-1.890
|
-1.055
|
-0.7633
|
-1.030
|
Free Cash Flow
1 |
-
|
-2.28
|
-33.66
|
-59.6
|
-
|
-27
|
-41
|
-58
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-6,666.67%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/8/20
|
3/22/21
|
3/29/22
|
3/28/23
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.71
|
-21.63
|
-19.62
|
-15.59
|
-15.42
|
-15.1
|
-11.66
|
-10.32
|
-5.533
|
-7.478
|
-6.863
|
-6.746
|
-6.99
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-16.88
|
-13.64
|
-14.34
|
-11.15
|
-9.715
|
-4.95
|
-12.43
|
-6.413
|
-6.311
|
-6.51
|
Net income
1 |
-
|
-
|
-
|
-16.88
|
-13.64
|
-14.34
|
-11.15
|
-9.715
|
-4.95
|
-12.43
|
-7.056
|
-7.106
|
-7.305
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-0.8000
|
-0.6500
|
-0.6800
|
-0.5200
|
-0.4600
|
-0.2300
|
-0.5800
|
-0.2050
|
-0.2050
|
-0.2400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/28/23
|
5/11/23
|
8/7/23
|
11/14/23
|
3/29/24
|
5/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
52.5
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2.28
|
-33.7
|
-59.6
|
-
|
-27
|
-41
|
-58
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.26
|
-
|
-
|
-
|
1
|
1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
114.94%
|
Announcement Date
|
3/22/21
|
3/29/22
|
3/28/23
|
3/29/24
|
-
|
-
|
-
|
Last Close Price
0.7211
USD Average target price
7
USD Spread / Average Target +870.74% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.89% | 21.85M | | +19.33% | 125B | | +13.95% | 109B | | -3.53% | 24.74B | | +2.71% | 22.67B | | -9.95% | 18.14B | | -41.48% | 16.67B | | -12.62% | 16.64B | | +0.99% | 13.45B | | +21.79% | 11.32B |
Bio Therapeutic Drugs
|